Antibiotic Resistance Lab Network
Generated by GPT-5-miniExpansion Funnel Raw 84 → Dedup 0 → NER 0 → Enqueued 0
| Antibiotic Resistance Lab Network | |
|---|---|
| Name | Antibiotic Resistance Lab Network |
| Abbreviation | AR Lab Network |
| Formation | 2016 |
| Purpose | Antimicrobial resistance surveillance and response |
| Region served | United States |
| Parent organization | Centers for Disease Control and Prevention |
Antibiotic Resistance Lab Network The Antibiotic Resistance Lab Network is a national laboratory initiative coordinating clinical, public health, and research laboratories to detect and respond to antimicrobial resistance. It links federal, state, and local entities to improve detection of resistant pathogens and inform interventions, integrating activities across laboratory systems, hospital settings, and public health programs. The Network interfaces with multiple agencies and institutions to provide data for policy, clinical practice, and global reporting.
Overview
The Network operates as a collaboration among the Centers for Disease Control and Prevention, Food and Drug Administration, National Institutes of Health, Department of Health and Human Services, Association of Public Health Laboratories, Council of State and Territorial Epidemiologists, State Health Departments, local health departments, and academic medical centers such as Johns Hopkins Hospital, Mayo Clinic, Massachusetts General Hospital, University of California, San Francisco Medical Center, University of Pennsylvania Health System. It performs coordinated laboratory testing for pathogens including Escherichia coli, Klebsiella pneumoniae, Staphylococcus aureus, Pseudomonas aeruginosa, Enterococcus faecalis, Neisseria gonorrhoeae, Salmonella enterica, and Campylobacter jejuni. The Network contributes to surveillance systems used by World Health Organization, Pan American Health Organization, European Centre for Disease Prevention and Control, and national programs such as UK Health Security Agency and Public Health Agency of Canada.
History and Development
The Network was initiated following recognition of antimicrobial resistance threats highlighted by publications from World Health Organization panels and reports by Institute of Medicine (US), later known as the National Academy of Medicine. Early development drew on laboratory capacity demonstrated during responses to outbreaks investigated by CDC Epidemic Intelligence Service officers and lessons from programs run by European Antimicrobial Resistance Surveillance Network and the Global Antimicrobial Resistance Surveillance System. Funding and strategic guidance involved collaborations with the Bill & Melinda Gates Foundation, the Robert Wood Johnson Foundation, and congressional mandates related to the Antimicrobial Resistance Solutions Act. Pilot phases coordinated with statewide initiatives in California Department of Public Health, New York State Department of Health, and Texas Department of State Health Services.
Structure and Participating Laboratories
The Network comprises regional reference laboratories, state public health laboratories, clinical hospital laboratories, and academic research labs. Participating institutions include laboratory systems at Children's Hospital of Philadelphia, Cleveland Clinic, Stanford Health Care, University of Washington Medical Center, Vanderbilt University Medical Center, Emory University Hospital, University of Michigan Health System, Duke University Hospital, UCLA Health, and public health labs such as the Washington State Department of Health Public Health Laboratories and the Florida Department of Health Bureau of Public Health Laboratories. It links to federal reference facilities at CDC National Center for Emerging and Zoonotic Infectious Diseases, FDA Center for Devices and Radiological Health, and research centers like Broad Institute and Rocky Mountain Laboratories. Governance involves advisory input from bodies such as National Institutes of Health Clinical Center, Advisory Committee on Immunization Practices, and professional societies including Infectious Diseases Society of America and American Society for Microbiology.
Surveillance Activities and Methods
Laboratory methods include phenotypic susceptibility testing, genotypic assays, whole-genome sequencing, and molecular surveillance. Techniques are standardized using frameworks from Clinical and Laboratory Standards Institute, protocols informed by World Health Organization guidance, and genomic pipelines used in collaborations with Wellcome Sanger Institute and National Center for Biotechnology Information. Surveillance targets multidrug-resistant organisms identified in clinical isolates from hospitals like Mount Sinai Hospital and community settings monitored by Kaiser Permanente Northern California. The Network supports detection of resistance mechanisms such as carbapenemases documented in New Delhi metallo-beta-lactamase literature and plasmid-mediated colistin resistance studied in academic outputs from Harvard Medical School and Yale School of Medicine.
Data Management and Reporting
Data systems integrate laboratory results into public health reporting platforms maintained by the Centers for Disease Control and Prevention and shared with partners like World Health Organization through international reporting streams. Interoperability efforts align with standards promoted by Health Level Seven International, data analyses use tools developed at Los Alamos National Laboratory and bioinformatics resources at National Center for Biotechnology Information and European Nucleotide Archive. Reporting supports clinical decision-making in hospitals such as Beth Israel Deaconess Medical Center and informs policy debates in entities like United States Congress and advisory committees at the National Academies of Sciences, Engineering, and Medicine.
Research, Training, and Capacity Building
The Network conducts research into resistance mechanisms in collaboration with institutions such as Columbia University Irving Medical Center, Cornell University Weill Medical College, University of Chicago Medicine, and Michigan State University. Training programs are coordinated with workforce initiatives from Association of Public Health Laboratories and fellowship tracks associated with the CDC Epidemic Intelligence Service and National Institutes of Health training grants. Capacity building includes technology transfer to state labs, partnerships with global health programs at Johns Hopkins Bloomberg School of Public Health, London School of Hygiene & Tropical Medicine, and laboratory strengthening efforts with Centers for Disease Control and Prevention Foundation.
Impact and Public Health Outcomes
The Network has informed outbreak investigations involving carbapenem-resistant Enterobacteriaceae reported in healthcare systems like NYU Langone Health and guided public health interventions resulting in changes to stewardship policies endorsed by Infectious Diseases Society of America and Society for Healthcare Epidemiology of America. Its genomic surveillance has contributed to publications in journals affiliated with American Association for the Advancement of Science and informed guidance from World Health Organization and national agencies such as Food and Drug Administration and Centers for Medicare & Medicaid Services. Outcomes include improved detection timelines at state labs, enhanced data sharing between institutions like Yale New Haven Health and Northwestern Memorial Hospital, and strengthened links to international surveillance networks coordinated with Pan American Health Organization.